There’s a growing idea in the biohacking space that if one intervention is helpful, combining several should be more effective. So people begin layering NAD⁺ with peptides, sometimes adding hormone therapies on top, often based on something they heard on a podcast or read online. None of that is controversial. Where things begin to break down is in how these therapies are combined.
Over the past few years, I’ve noticed a shift in how high-performing patients approach their health.
They’re not waiting to feel sick. They’re trying to stay sharp, recover faster, and extend how long they can operate at a high level. Naturally, that’s led many of them into the world of peptides, NAD⁺ therapy, and hormone optimization.
Most don’t come in asking whether these therapies work. They come in already using them.
What they’re usually missing is not access. It’s structure.
There’s a growing idea in the biohacking space that if one intervention is helpful, combining several should be more effective. So people begin layering NAD⁺ with peptides, sometimes adding hormone therapies on top, often based on something they heard on a podcast or read online.
I understand the appeal. There is real science behind many of these compounds.
NAD⁺ plays a central role in cellular energy production and DNA repair. As levels decline with age, we see changes in energy, cognition, and metabolic function. In the right setting, restoring those levels can be meaningful.
Peptides, depending on the type, can influence tissue repair, inflammation, growth hormone signaling, and even aspects of gut function. Compounds like BPC-157 or CJC-1295 with Ipamorelin have legitimate clinical applications when used appropriately.
Hormone optimization, when carefully managed, can improve energy stability, body composition, sleep, and cognitive clarity.
None of that is controversial.
Where things begin to break down is in how these therapies are combined.
Human physiology doesn’t respond well to being pushed in multiple directions at once, especially when those directions involve overlapping endocrine and inflammatory pathways. When several compounds are introduced simultaneously, it becomes difficult to predict how the system will respond. More importantly, it becomes difficult to understand what is actually driving the outcome.
I routinely see patients who believed they were optimizing their health, only to find subtle disruptions beginning to show up in their labs. Changes in glucose regulation. Shifts in thyroid signaling. Suppression of endogenous hormone production. Sometimes low-grade inflammation that wasn’t there before.
These are not reckless individuals. Most are disciplined, thoughtful, and highly motivated. What they’ve been missing is sequencing.
At Diamond, we take a different approach.
We don’t stack therapies upfront. We build them deliberately, one at a time.
Before introducing anything, we establish a clear baseline. That includes hormone levels, metabolic markers, inflammatory signals, and a broader understanding of how our member is functioning day to day. From there, we introduce a single intervention with a specific purpose.
If we’re using NAD⁺, we’re looking at energy production, recovery capacity, and cognitive function. We monitor the response, both subjectively and through objective markers. Only after we understand that response do we consider adding another layer, whether that’s a peptide for recovery or a hormone adjustment if it’s clinically appropriate.
It’s a slower process on the front end, but it’s far more precise.
There’s also a sourcing issue that deserves more attention than it gets. Many of the peptides being used outside of clinical settings are labeled for research use only. That isn’t a technicality. It means there’s no guarantee of purity, no consistency in dosing, and no oversight in how the compound was produced or stored. When multiple products from questionable sources are combined, the margin for error widens considerably.
The other piece, which is less often discussed, is behavioral.
High performers are used to solving problems by adding tools. In business, that instinct is often rewarded. In physiology, it can create unnecessary complexity. The body doesn’t usually benefit from more variables. It benefits from the right variable, introduced at the right time.
That’s really the difference between stacking and a protocol.
A stack is an accumulation. A protocol is a sequence.
When these therapies are used thoughtfully, they can be extremely effective. NAD⁺, peptides, and hormone optimization all have a place in performance medicine. The question is not whether they work. The question is how they’re being used, and whether anyone is actually accountable for the outcome.
Optimization, if it’s done well, is not aggressive. It’s disciplined.
It requires knowing when to intervene, when to wait, and when to stop.
If you’re already using peptides or considering more advanced therapies, the most important next step isn’t adding something new. It’s understanding where you are starting from and whether your current approach has any structure behind it.
That’s where the difference tends to show up over time.
At Diamond, we don’t build stacks.
We build strategies.
Author: Dr. James Pinckney
CEO & Founder Diamond Health